Evolve Global Healthcare Enh Yld A Hdg (EVF170)
20.29
+0.29 (+1.47%)
CAD |
May 20 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.81% | 228.11M | 7.74% | 44.05% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| 83.04M | 5.43% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| LIFE seeks to replicate, to the extent reasonably possible before fees and expenses, the performance of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while mitigating downside risk. LIFE invests primarily in the equity constituents of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while writing covered call options on up to 33% of the portfolio securities, at the discretion of the Manager. The level of covered call option writing may vary based on market volatility and other factors. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | -- |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl Mkts GR CAD |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Evolve Funds Group Inc |
| Prospectus Benchmark Index | |
| Solactive Glb Healthcare 20 Hdg PR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 2.43 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
21
83.04M
-338.90M
Category Low
449.74M
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Merck & Co Inc
|
5.53% | -- | -- |
|
Novo Nordisk A/S ADR
|
5.39% | -- | -- |
|
Bristol-Myers Squibb Co
|
5.33% | -- | -- |
|
GlaxoSmithKline PLC ADR
|
5.30% | -- | -- |
|
CSL Ltd ADR
|
5.26% | -- | -- |
|
Johnson & Johnson
|
5.20% | -- | -- |
|
Eli Lilly and Co
|
5.12% | -- | -- |
|
Novartis AG ADR
|
5.05% | -- | -- |
|
AstraZeneca PLC ADR
|
5.04% | -- | -- |
|
Pfizer Inc
|
5.02% | -- | -- |
Basic Info
| Investment Strategy | |
| LIFE seeks to replicate, to the extent reasonably possible before fees and expenses, the performance of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while mitigating downside risk. LIFE invests primarily in the equity constituents of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while writing covered call options on up to 33% of the portfolio securities, at the discretion of the Manager. The level of covered call option writing may vary based on market volatility and other factors. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | -- |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl Mkts GR CAD |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Evolve Funds Group Inc |
| Prospectus Benchmark Index | |
| Solactive Glb Healthcare 20 Hdg PR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 2.43 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-20-22) | 7.74% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield (4-28-22) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 22.36 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of April 30, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 7/7/2020 |
| Last Annual Report Date | 12/31/2021 |
| Last Prospectus Date | 8/16/2021 |
| Share Classes | |
| EVF171 | Fee-based Advice |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |